WAVE Life Sciences Ltd. (NASDAQ:WVE) Stock Has Consensus Target Price of $22.31 According to Analysts

WAVE Life Sciences Ltd. (NASDAQ:WVE) has received a consensus rating of “Moderate Buy” from the eighteen ratings firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and fifteen have given a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $21.59.

A number of analysts recently weighed in on WVE shares. Mizuho cut their target price on WAVE Life Sciences from $27.00 to $23.00 and set an “outperform” rating for the company in a research note on Tuesday, August 4th. Wall Street Zen downgraded shares of WAVE Life Sciences from a “hold” rating to a “strong sell” rating in a research note on Saturday, August 1st. UBS Group set a $13.00 price target on shares of WAVE Life Sciences in a research note on Monday, August 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of WAVE Life Sciences in a report on Friday, July 17th. Finally, LADENBURG THALM/SH SH initiated coverage on shares of WAVE Life Sciences in a research note on Thursday. They issued a “buy” rating and a $10.00 price objective for the company.

WAVE Life Sciences Stock Up 4.9%

NASDAQ WVE opened at $3.88 on Tuesday. The stock’s 50-day simple moving average is $4.99 and its two-hundred day simple moving average is $6.27. WAVE Life Sciences has a twelve month low of $3.56 and a twelve month high of $21.73. The company has a market capitalization of $764.55 million, a price-to-earnings ratio of -3.56 and a beta of -1.42.

WAVE Life Sciences (NASDAQ:WVE) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.04). The firm had revenue of $2.27 million during the quarter, compared to analysts’ expectations of $7.45 million. WAVE Life Sciences had a negative return on equity of 50.36% and a negative net margin of 309.73%. On average, equities analysts expect that WAVE Life Sciences will post -1.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other WAVE Life Sciences news, Director Adrian Rawcliffe sold 12,700 shares of the business’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $5.29, for a total value of $67,183.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Heidi Wagner sold 7,000 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $6.01, for a total transaction of $42,070.00. Following the sale, the director owned 44,930 shares of the company’s stock, valued at approximately $270,029.30. The trade was a 13.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 23,564 shares of company stock worth $132,476. 24.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On WAVE Life Sciences

A number of large investors have recently bought and sold shares of the stock. Readystate Asset Management LP purchased a new stake in shares of WAVE Life Sciences during the second quarter worth about $27,465,000. Squarepoint Ops LLC increased its holdings in WAVE Life Sciences by 68.0% during the 2nd quarter. Squarepoint Ops LLC now owns 2,541,442 shares of the company’s stock valued at $14,766,000 after purchasing an additional 1,029,052 shares during the period. Eventide Asset Management LLC purchased a new position in WAVE Life Sciences during the 4th quarter valued at about $8,500,000. Elmind Capital LP bought a new position in WAVE Life Sciences during the 4th quarter valued at approximately $7,613,000. Finally, Renaissance Technologies LLC raised its position in WAVE Life Sciences by 152.6% during the 1st quarter. Renaissance Technologies LLC now owns 597,220 shares of the company’s stock valued at $4,330,000 after purchasing an additional 360,800 shares during the last quarter. 89.73% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting WAVE Life Sciences

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: FDA supports WVE-006 registrational pathway: Following discussions with the FDA, WAVE said it plans to evaluate its RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD) in a single two-year registrational trial. A one-year interim analysis could support an application for accelerated approval based on AATD biomarkers, potentially shortening the path to commercialization. WAVE Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006
• Positive Sentiment: Regulatory clarity lifts the lead program: Multiple reports said the FDA feedback supports WVE-006’s development plan, reducing uncertainty around trial design and providing a clearer route toward potential registration. This is particularly important for WAVE because WVE-006 is a key value driver for the company. Wave Life Sciences gets FDA backing for WVE-006 registrational trial
• Positive Sentiment: GSK advances a partnered siRNA program: GSK selected a liver-focused siRNA program developed with WAVE for further development, triggering a $12 million milestone payment. Three additional collaboration programs are also advancing, offering non-dilutive funding and validation of WAVE’s SpiNA siRNA technology. WAVE Life Sciences Announces GSK’s Selection of siRNA Program
• Positive Sentiment: Analyst endorsement: Ladenburg Thalmann initiated coverage with a Buy rating and a $10 price target, implying substantial upside from the recent trading level. The target reflects optimism about WVE-006 and the company’s broader pipeline, although it remains dependent on clinical execution.
• Negative Sentiment: Clinical and financial risks remain: WVE-006 still requires successful clinical development and regulatory review, while WAVE continues to report losses and limited revenue. Its latest quarterly results missed consensus estimates for both earnings and revenue, so additional financing or development setbacks could weigh on the stock.

About WAVE Life Sciences

WAVE Life Sciences Ltd. (NASDAQ: WVE) is a biotechnology company focused on developing medicines that target RNA, the biological molecule that helps translate genetic information into proteins. The company uses its oligonucleotide chemistry and delivery technologies to pursue treatments for genetically defined diseases, including conditions affecting the liver, muscles and nervous system.

WAVE’s research programs include RNA editing medicines designed to correct or modify disease-related genetic messages without permanently altering DNA.